NO20084317L - Metoder for a behandle lupus ved bruk av CD4 antistoff - Google Patents

Metoder for a behandle lupus ved bruk av CD4 antistoff

Info

Publication number
NO20084317L
NO20084317L NO20084317A NO20084317A NO20084317L NO 20084317 L NO20084317 L NO 20084317L NO 20084317 A NO20084317 A NO 20084317A NO 20084317 A NO20084317 A NO 20084317A NO 20084317 L NO20084317 L NO 20084317L
Authority
NO
Norway
Prior art keywords
methods
antibody
lupus
depleting
administration
Prior art date
Application number
NO20084317A
Other languages
English (en)
Inventor
Bryan Irving
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of NO20084317L publication Critical patent/NO20084317L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Sammendrag Fremgangsmåter for behandling av lupus som inkluderer systemisk lupus erytematose, kutant lupus erytemetose og lupus nefritt, er tilveiebrakt. Fremgangsmåtene involverer administrasjon av en kombinasjon av et ikke-deplerende CD4-antistoff og en annen forbindelse anvendt klinisk eller eksperimentelt for behandling av lupus. Fremgangsmåter for behandling av lupus nefritt ved administrasjon av et ikke-deplerende CD4antistoff som resulterer i en forbedring i renal funksjon og/eller en reduksjon i proteinuri eller aktiv urinsediment er også tilveiebrakt. Fremgangsmåter for behandling av multippel sklerose ved administrasjon av et ikke-deplerende CD4-antistoff, eventuelt i kombinasjon med en andre forbindelse anvendt klinisk eller eksperimentelt for å behandle MS, er beskrevet. Fremgangsmåter for behandling av transplantatresipienter og subjekter med reumatoid artritt, astma, psoriasis, Crohns sykdom, ulcerativ kolitt og Sjogrens syndrom, er også tilveiebrakt.
NO20084317A 2006-03-16 2008-10-15 Metoder for a behandle lupus ved bruk av CD4 antistoff NO20084317L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78353506P 2006-03-16 2006-03-16
US87388106P 2006-12-07 2006-12-07
PCT/US2007/006443 WO2007109052A2 (en) 2006-03-16 2007-03-14 Methods of treating lupus using cd4 antibodies

Publications (1)

Publication Number Publication Date
NO20084317L true NO20084317L (no) 2008-12-09

Family

ID=38522934

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084317A NO20084317L (no) 2006-03-16 2008-10-15 Metoder for a behandle lupus ved bruk av CD4 antistoff

Country Status (12)

Country Link
US (1) US20070218062A1 (no)
EP (1) EP2001510A4 (no)
JP (1) JP2009530290A (no)
KR (1) KR20080112300A (no)
AU (1) AU2007227609A1 (no)
BR (1) BRPI0708902A2 (no)
CA (1) CA2645322A1 (no)
IL (1) IL193920A0 (no)
MX (1) MX2008011785A (no)
NO (1) NO20084317L (no)
RU (1) RU2008137765A (no)
WO (1) WO2007109052A2 (no)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5642549B2 (ja) 2007-10-12 2014-12-17 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 複数の核酸からのタンパク質発現
ES2610327T3 (es) * 2008-03-13 2017-04-27 Biotest Ag Régimen de dosificación de anticuerpos anti-CD4 para el tratamiento de enfermedades autoinmunitarias
BRPI0909048A2 (pt) * 2008-03-13 2015-11-24 Biotest Ag composição farmacêutica, e, método de tratamento de uma doença autoimune
HUE028962T2 (en) 2008-03-13 2017-01-30 Biotest Ag Active ingredient for treating disease
AR077718A1 (es) * 2008-07-15 2011-09-21 Genentech Inc Metodos para tratar enfermedades autoinmunes usando anticuerpos anti cd4. formulacion farmaceutica
US9115399B2 (en) * 2008-09-23 2015-08-25 The Trustees Of The University Of Pennsylvania Recombination sequence (RS) rearrangement frequency as a measure of central B cell tolerance
KR20110061630A (ko) * 2008-09-29 2011-06-09 바이오테스트 아게 질병 치료용 조성물
NZ592420A (en) 2008-10-02 2012-12-21 Emergent Product Dev Seattle Cd86 antagonist multi-target binding proteins
EP3524620A1 (en) * 2008-10-14 2019-08-14 Genentech, Inc. Immunoglobulin variants and uses thereof
BR112012007778A2 (pt) 2009-10-07 2020-08-11 Genentech, Inc. método para identificar lúpus, método para avaliar se um sujeito está em risco de desenvolver lúpus, medicamentos para tratar uma condição de lupus, método e usos de um agente terapêutico.
GB0920944D0 (en) 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
CN102791130B (zh) * 2010-03-03 2015-02-25 泰华制药工业有限公司 使用拉喹莫德治疗狼疮肾炎
DE102011082871A1 (de) * 2011-09-16 2013-03-21 Florian, Prof. Dr. Lang Therapeutische und diagnostische Targets für Autoimmunität, inflammatorische Prozesse und/oder immuner Pathogenese und/oder von Erkrankungen, welche auf Autoimmunität, inflammatorische Prozessen und/oder immuner Pathogenese beruhen
CN106063787A (zh) 2012-02-03 2016-11-02 泰华制药工业有限公司 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途
JP2015535287A (ja) 2012-11-07 2015-12-10 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドのアミン塩
NZ630427A (en) 2013-03-14 2017-06-30 Teva Pharma Crystals of laquinimod sodium and improved process for the manufacture thereof
WO2015099167A1 (ja) 2013-12-27 2015-07-02 国立大学法人大阪大学 Ｉｌ－１７ａを標的とするワクチン
SG11201708795TA (en) 2015-04-28 2017-11-29 Orphidia Ltd Analyte detection and methods therefor
KR102721494B1 (ko) * 2018-04-17 2024-10-24 국립암센터 고갈성 항 cd4 단일클론항체를 포함하는 항암 t 세포치료제 보조용 조성물 및 이의 용도
WO2023015217A1 (en) 2021-08-04 2023-02-09 Sana Biotechnology, Inc. Use of cd4-targeted viral vectors
US20250059560A1 (en) 2021-12-16 2025-02-20 Sana Biotechnology, Inc. Methods and systems of particle production
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
US20250144235A1 (en) 2022-02-02 2025-05-08 Sana Biotechnology, Inc. Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
US20250222027A1 (en) 2022-04-01 2025-07-10 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
WO2024026377A1 (en) 2022-07-27 2024-02-01 Sana Biotechnology, Inc. Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
CN115364210A (zh) * 2022-08-12 2022-11-22 浙江中医药大学 一种cd4中和抗体在制备治疗狼疮脑病的药物中的应用
US20260055146A1 (en) 2022-08-24 2026-02-26 Sana Biotechnology, Inc. Delivery of heterologous proteins
US20260098062A1 (en) 2022-09-21 2026-04-09 Sana Biotechnology, Inc. Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
WO2024220597A2 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Digital droplet based assay for detecting replication competent lentiviral vector
KR20260016952A (ko) 2023-05-23 2026-02-04 사나 바이오테크놀로지, 인크. 탠덤 퓨소젠 및 관련 지질 입자
WO2025184529A1 (en) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Viral particles with fusogen display and related compositions and methods

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US77275A (en) * 1868-04-28 Improvement in tee manufacture of packing foe steam-engines
US4381295A (en) * 1979-04-26 1983-04-26 Ortho Pharmaceutical Corporation Monoclonal antibody to human helper T cells and methods of preparing same
US4690905A (en) * 1983-11-16 1987-09-01 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method for removal of human antibodies to native DNA from serum
US4695459A (en) * 1984-12-26 1987-09-22 The Board Of Trustees Of Leland Stanford Junior University Method of treating autoimmune diseases that are mediated by Leu3/CD4 phenotype T cells
US6685941B1 (en) * 1988-11-23 2004-02-03 The Regents Of The University Of Michigan Methods of treating autoimmune disease via CTLA-4Ig
US5690933A (en) * 1989-05-31 1997-11-25 Glaxo Wellcome Inc. Monoclonal antibodies for inducing tolerance
GB9100741D0 (en) * 1991-01-14 1991-02-27 Univ London Treatment of disease
US5756096A (en) * 1991-07-25 1998-05-26 Idec Pharmaceuticals Corporation Recombinant antibodies for human therapy
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
IE922437A1 (en) * 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
WO1994004188A1 (en) * 1992-08-21 1994-03-03 Genentech, Inc. Method for treating an lfa-1-mediated disorder
WO1998026086A1 (en) * 1996-12-11 1998-06-18 University Of Florida Novel methods and compositions for treatment of autoimmune diseases
GB2376466A (en) * 2001-06-14 2002-12-18 Mark Frewin TRX1 antibody
US7541443B2 (en) * 2001-06-14 2009-06-02 Tolerrx, Inc. Anti-CD4 antibodies
EP1765400A2 (en) * 2004-06-04 2007-03-28 Genentech, Inc. Method for treating lupus
TW201422238A (zh) * 2004-06-04 2014-06-16 Genentech Inc Ｃｄ２０抗體於治療多發性硬化症之用途及用於該用途之物品
US20060002921A1 (en) * 2004-06-22 2006-01-05 Tolerrx, Inc. Optimized dosing with anti-CD4 antibodies for tolerance induction in primates

Also Published As

Publication number Publication date
KR20080112300A (ko) 2008-12-24
IL193920A0 (en) 2011-08-01
US20070218062A1 (en) 2007-09-20
MX2008011785A (es) 2008-09-25
AU2007227609A1 (en) 2007-09-27
RU2008137765A (ru) 2010-04-27
EP2001510A4 (en) 2010-06-09
WO2007109052A3 (en) 2008-12-11
WO2007109052A2 (en) 2007-09-27
BRPI0708902A2 (pt) 2011-06-14
EP2001510A2 (en) 2008-12-17
CA2645322A1 (en) 2007-09-27
JP2009530290A (ja) 2009-08-27

Similar Documents

Publication Publication Date Title
NO20084317L (no) Metoder for a behandle lupus ved bruk av CD4 antistoff
NO20090093L (no) Profylaktisk eller terapeutisk middel for inflammatorisk sykdom
AR093106A1 (es) Silicato de zirconio microporoso para el tratamiento de la hipercalemia
TWI455947B (zh) 拮抗性對抗人的ｃｄ４０單株抗體
Reisman et al. Treatment of BK virus‐associated nephropathy with CMX 001 after kidney transplantation in a young child
Mansuri et al. Working memory impairments in children with stuttering
Longshan et al. Current status of pediatric kidney transplantation in China: data analysis of Chinese Scientific Registry of Kidney Transplantation
Katsaros et al. Transcatheter aortic valve implantation access sites: same goals, distinct aspects, various merits and demerits
WO2007103273A3 (en) Thioredoxin and thioredoxin reductase inhibitors
SG10201809955SA (en) Method for manufacturing composition comprising local anesthetic, heparinoid, and buffer
Vela et al. Conversion to mTOR-inhibitors plus IV immunoglobulins in kidney-transplant recipients with BKV infection: a retrospective comparative study
NO20055884L (no) Asenanin for behandling av schizofreni hos en pasient med overvekt eller predisposisjon for overvekt
Chopade et al. Determination of the mitigating effect of colon-specific bioreversible codrugs of mycophenolic acid and aminosugars in an experimental colitis model in Wistar rats
Ustun Resolution of osteosclerosis after alloHCT in systemic mastocytosis
NO20074825L (no) Piperidinylpiperazinderivater for anvendelse som inhibitorer av kjemokinreseptorer
WO2017126700A9 (ja) 小胞型ヌクレオチドトランスポーター活性阻害剤
Stasinopoulou et al. The Anti-Atherosclerotic Effects of Endothelin Receptor Antagonist, Bosentan, in Combination with Atorvastatin—An Experimental Study
WO2006044665A3 (en) Neuroprotective spirostenol pharmaceutical compositions
Chaúque et al. Promising Drug Repurposing Candidates Targeting Free-Living Amoebae: A Systematic and Critical Review of Laboratory-Based Evidence
Park et al. Outcome of cadaveric kidney transplantation from expanded criteria donors
Leblanc EAGER: Carbon Dot-Based Transformative COVID-19 Therapy
Coates Canadian Studies: in Canada and abroad
Counsell COVID-19 Brief: How is the disease best treated? Results from the RECOVERY and SOLIDARITY clinical trials provide important answers
Min et al. Validation of Recently Proposed Risk and Prognostic Factors for Thrombotic Microangiopathy after Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia
WO2022074698A3 (en) Anatoxins and antibodies for use in the prevention and treatment of coronavirus disease

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application